Back to Search
Start Over
1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC).
- Source :
-
Annals of Oncology . 2020 Supplement 4, Vol. 31, pS820-S820. 1p. - Publication Year :
- 2020
- Subjects :
- *NON-small-cell lung carcinoma
*IPILIMUMAB
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 31
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 152696112
- Full Text :
- https://doi.org/10.1016/j.annonc.2020.08.1583